[1] Novo E, Cannito S, Paternostro C, et al. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys, 2014, 548:20-37.
[2] Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol, 2013, 3:1473-1492.
[3] Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol, 2014, 5:177.
[4] Ferris WF, Crowther NJ. Once fat was fat and that was that: our changing perspectives on adipose tissue. Cardiovasc J Afr, 2011, 22:147-154.
[5] Polyzos SA, Mantzoros CS. Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism, 2015, 64:5-12.
[6] Polyzos SA, Kountouras J, Mantzoros CS. Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism, 2015, 64:60-78.
[7] Tang Y. Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Dig Dis Sci, 2015, 60:1554-1564.
[8] Chung HK, Kim YK, Park JH, et al. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Liver Int, 2015, 35:1341-1353.
[9] Costantini S, Capone F, Maio P, et al. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncol Rep, 2013, 29:2163-2168.
[10] Zhai X, Yan K, Fan J, et al. The beta-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br J Pharmacol, 2013, 169:197-212.
[11] Kukla M, Mazur W, Buldak RJ, et al. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med, 2011, 17:1397-1410.
[12] Trak-Smayra V, Paradis V, Massart J, et al. Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol, 2011, 92:413-421.
[13] Yang YY, Huang YT, Tsai TH, et al. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis. Clin Sci (Lond), 2012, 123:669-680.
[14] Yan K, Deng X, Zhai X, et al. p38 mitogen-activated protein kinase and liver X receptor-alpha mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med, 2012, 18:10-18.
[15] Zhang W, Niu M, Yan K, et al. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. Int J Biochem Cell Biol, 2013, 45:736-744.
[16] Duval F, Moreno-Cuevas JE, Gonzalez-Garza MT, et al. Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells. Adv Pharmacol Sci, 2014, 2014:373295.
[17] Zhou Q, Guan W, Qiao H, et al. GATA binding protein 2 mediates leptin inhibition of PPARgamma1 expression in hepatic stellate cells and contributes to hepatic stellate cell activation. Biochim Biophys Acta, 2014, 1842:2367-2377.
[18] Liu Y, Brymora J, Zhang H, et al. Leptin and acetaldehyde synergistically promotes alphaSMA expression in hepatic stellate cells by an interleukin 6-dependent mechanism. Alcohol Clin Exp Res, 2011, 35:921-928.
[19] Zhao L, Fu Z, Liu Z. Adiponectin and insulin cross talk: the microvascular connection. Trends Cardiovasc Med, 2014, 24:319-324.
[20] Handy JA, Fu PP, Kumar P, et al. Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J, 2011, 440:385-395.
[21] Briggs DB, Giron RM, Malinowski PR, et al. Role of redox environment on the oligomerization of higher molecular weight adiponectin. BMC Biochem, 2011, 12:24.
[22] Vrachnis N, Belitsos P, Sifakis S, et al. Role of adipokines and other inflammatory mediators in gestational diabetes mellitus and previous gestational diabetes mellitus. Int J Endocrinol, 2012, 2012:549748.
[23] Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol, 2011, 17:2801-2811.
[24] Ahsan MK, Mehal WZ. Activation of adenosine receptor A2A increases HSC proliferation and inhibits death and senescence by down-regulation of p53 and Rb. Front Pharmacol, 2014, 5:69.
[25] Kumar P, Smith T, Rahman K, et al. Adiponectin modulates focal adhesion disassembly in activated hepatic stellate cells: implication for reversing hepatic fibrosis. FASEB J, 2014, 28:5172-5183.
[26] Hsu CS, Liu WL, Chao YC, et al. Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection. Hepatol Int, 2015, 9:231-242.
[27] Pepping JK, Otvos L Jr, Surmacz E, et al. Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors. J Neuroimmune Pharmacol, 2014, 9:388-398.
[28] Mera K, Uto H, Mawatari S, et al. Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C. BMC Gastroenterol, 2014, 14:27.
[29] Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood), 2012, 237:1-9.
[30] Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol, 2012, 227:493-507.
[31] Nobili V, Carpino G, Alisi A, et al. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology, 2012, 56:2142-2153.
[32] Dong ZX, Su L, Brymora J, et al. Resistin mediates the hepatic stellate cell phenotype. World J Gastroenterol, 2013, 19:4475-4485.
[33] Krist J, Wieder K, Kloting N, et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts, 2013, 6:57-69.
[34] Principe A, Melgar-Lesmes P, Fernandez-Varo G, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology, 2008, 48:1193-1201.
[35] Nan YM, Kong LB, Ren WG, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol mediated liver fibrosis in mice. Lipids Health Dis, 2013, 12:11. |
